Therapeutic Drug Monitoring of Levetiracetam (Keppra)
Routine therapeutic drug monitoring (TDM) of levetiracetam is NOT recommended for most patients, as the drug has predictable linear pharmacokinetics, minimal drug interactions, and a broad therapeutic window. 1
When TDM May Be Indicated
While the evidence explicitly states "no need for therapeutic drug monitoring" for levetiracetam 1, certain clinical scenarios warrant consideration:
Special Populations Where TDM May Be Useful:
Pregnancy: Levetiracetam clearance increases significantly during pregnancy, with levels declining as pregnancy progresses. One study showed 45 of 48 trough samples fell below the therapeutic range of 12-46 mg/L in pregnant women, with statistically significant differences between third and first trimesters 2, 3
Renal impairment: Levetiracetam clearance declines linearly with declining creatinine clearance. Patients with CrCL <60 mL/min require dose adjustments 4, 3, 5
Critically ill patients: May have augmented clearance requiring higher doses to maintain therapeutic levels 3
Pediatric patients: Clearance is 30-40% higher than adults, requiring weight-based dosing 3
Elderly patients (>65 years): Clearance decreased by almost 50% compared to adults 3
Patients on enzyme-inducing drugs: Co-administration with glucuronidation-inducing drugs increases clearance significantly 6
Therapeutic Reference Range
The accepted therapeutic reference range is 10-40 mg/L (or 12-46 mg/L in some references) 7, 8. However, this range has limited clinical utility because:
- Wide variability exists in concentration-response relationships 8
- No positive correlation has been consistently demonstrated between levetiracetam levels and efficacy or toxicity 3
- Adverse effects, seizures, and efficacy occur below, within, and above the supposed reference ranges 3
Clinical Application
When TDM is performed, use it to:
- Verify compliance in patients with breakthrough seizures
- Detect severe intoxication (though rare given the drug's safety profile)
- Establish an individual therapeutic range in special populations where pharmacokinetics are altered 3
One study suggested a threshold concentration of 11 mg/L for therapeutic response (sensitivity 73%, specificity 71%), though this was not statistically significant due to small sample size and refractory seizure types 8.
Important Caveats
- Monitor complete blood count rather than drug levels, as this is the recommended monitoring parameter 1
- Dose adjustments in renal dysfunction are based on creatinine clearance, not serum levels 4
- The FDA label makes no mention of routine TDM requirements 9
- Levetiracetam is generally well-tolerated with minimal neuropsychiatric events (3.6% incidence in one study) 10
In practice, clinical response and tolerability should guide dosing decisions rather than serum concentrations for most patients. Reserve TDM for the specific populations listed above where altered pharmacokinetics are expected or when compliance is questioned.